EMPB - Emergence et maturation de projets de biotechnologie à fort potentiel de valorisation (EMPB)
Utilisation diagnostique et thérapeutique d'anticorps spécifiques du marqueur tumoral gangliosidique GD2 O-acétylé – Theraximab
Project coordination
Jacques BARBET (Organisme de recherche)
The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.
Partner
Help of the ANR 148,701 euros
Beginning and duration of the scientific project:
- 18 Months
